

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Seipin/BSCL2 in direct ELISAs and Western blots.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human Seipin/BSCL2 Asn279-Ser398 Accession # Q96G97
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

BSCL2 (Bernardinelli-Seip Congenital Lipodystrophy type 2 protein; also Seipin) is a 70-74 kDa glycoprotein member of the seipin family of molecules. Although it has widespread expression, and has been specifically found in the endoplasmic reticulum (ER) of cortical and spinal motor neurons, basophils of the anterior pituitary, adipocytes and spermatids. Its function is unclear, but it is known to structurally resemble SREBPs, and thus may regulate gene transcription. Mutations are reported that involve its glycosylation site, causing protein misfolding and the initiation of apoptosis. Human BSCL2 is 398 amino acids (aa) in length. It contains two transmembrane segments (aa 27-47 and 243-263) plus an N-terminal (aa 1-26) and C-terminal (aa 264-398) cytoplasmic domain. BSCL2 is polyubiquitinated, and runs between 100-200 kDa in SDS-PAGE. There is an alternative start site 64 aa upstream of the standard site. This 462 aa isoform is considered to be the predominant isoform for BSCL2, and is associated with the 70-74 kDa MW cited above. There is one additional potential isoform variant that possesses a 63 aa substitution for aa 225-398. BSCL2 is reportedly cleaved, and generates a 40-41 kDa N-terminal fragment. Over aa 279-398, human BSCL2 shares 73% aa sequence identity with mouse BSCL2.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.